SAB Biotherapeutics (SABS)
Develops a fully human polyclonal-antibody therapy for newly diagnosed autoimmune diabetes.
Something off on this page? Send us feedback.
Develops SAB-142, an investigational fully human anti-thymocyte globulin for newly diagnosed autoimmune diabetes, using a transchromosomic-cattle platform to generate multi-specific polyclonal antibodies. Its development-stage model centers on clinical advancement and financing rather than commercial product sales.
Develops SAB-142, an investigational fully human anti-thymocyte globulin for newly diagnosed autoimmune diabetes. The therapy uses multi-specific polyclonal antibodies intended to modulate immune cells involved in pancreatic beta-cell destruction.
Runs the Tc Bovine/DiversitAb platform from a Miami Beach corporate office and a South Dakota research and manufacturing base, combining transchromosomic cattle, plasma collection, process development, and clinical-scale cGMP operations. Clinical activity extends across the United States, Australia, and New Zealand, with manufacturing support contracted in Canada.
Depends on the SAFEGUARD trial, regulatory review, animal-herd supply, specialized manufacturing, and continued financing. Has no approved product, commercial sales, marketing, or distribution operation.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jun 24, 2026 | Barclays | Initiate | Overweight | $13 | |
| May 20, 2026 | Jefferies | Target | $11 | ||
| May 12, 2026 | H.C. Wainwright | Target | $6 | $10 | |
| Jan 7, 2026 | UBS | Target | $7 | ||
| Sep 17, 2025 | Leerink Partners | Target | $7 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $102.6M · Total debt $5.1M · Total assets $238.2M · Shareholders' equity $214.8M
- Revenue
- $0
- Operating income
- −$23.4M
- Net income
- −$22.5M
No dividends on record.
| Institutions81 holders · as of Mar 31, 2026 | 76.05% | 69.19M shares | |
| Insiders1 holder · as of Jun 26, 2026 | 0.05% | 42.3K shares | |
| Otherremainder | 23.90% | 21.75M shares |
90.99M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Vivo Capital, LLCInstitution | 12.55% | 11.42M | 13Fas of Mar 31, 2026 |
Caligan Partners LPInstitution | 8.76% | 7.97M | 13Fas of Mar 31, 2026 |
Perceptive Advisors LLCInstitution | 7.07% | 6.43M | 13Fas of Mar 31, 2026 |
Adage Capital Management, L.P.Institution | 7.04% | 6.41M | 13Gfiled Aug 12, 2026 ↗ |
Commodore Capital LPInstitution | 4.84% | 4.40M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
No open-market trades in the last 12 months.
- Sanofi (ADR)
Approved Tzield and Thymoglobulin lead immune therapy and ATG overlap.
- Biomea Fusion
Icovamenib pursues beta-cell restoration in the same T1D population.
- Pfizer
Atgam is an established animal-derived ATG benchmark.
- vTv Therapeutics
Cadisegliatin is a Phase 3 oral adjunct for adult T1D.
- Sana Biotechnology
SC451 seeks insulin independence through immune-evasive islet replacement.
- Century Therapeutics
CNTY-813 targets a functional cure with iPSC-derived islets.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SAB Biotherapeutics | $3.60 | −4.00% | $341.2M | — | — | — | — |
| Sanofi (ADR) | $44.52 | +0.12% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Biomea Fusion | $1.92 | −0.65% | $139.9M | — | — | — | — |
| Pfizer | $28.99 | −0.14% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| vTv Therapeutics | $33.61 | +5.20% | $87.4M | — | — | 2.4 | — |
| Sana Biotechnology | $3.95 | +1.28% | $1.08B | — | — | — | — |
| Century Therapeutics | $1.91 | −9.91% | $182.7M | — | — | — | — |
| Median | 58.3 | 10.4 | 2.4 | +6.9% |